E-Mail
IMAGE: Sean Paz, co-author and a graduate student in FAU s Schmidt College of Medicine, loads COVID-19 tests in a PCR (polymerase chain reaction) machine. This laboratory apparatus is most commonly used. view more
Credit: Florida Atlantic University
To properly monitor and help curb the spread of COVID-19, several millions of diagnostic tests are required daily in just the United States alone. There is still a widespread lack of COVID-19 testing in the U.S. and many of the clinical diagnostics protocols require extensive human labor and materials that could face supply shortages and present biosafety concerns.
The current gold standard for COVID-19 diagnostic testing in the U.S., developed by the U.S. Centers for Disease Control and Prevention (CDC), is quantitative PCR-based (qPCR) molecular tests that detect the presence of the viral nucleic acid. Although highly accurate, these CDC-approved tests require specialized reagents, equipment, and personnel train
is projected to reach USD 5.31 billion by 2027 according to a new study conducted by Polaris Market Research the market is anticipated to register a
CAGR of 5.1% from 2020 to 2027. An increasingly aging population has gradually resulted in a rise of cases of lewy body dementia, which is one of the primary factors driving the growth of the global market. A higher number of dementia cases in developed countries are creating strong demand for effective drugs and leading manufacturers bringing new products tailored to cure the disease are expected to fuel significant demand for dementia treatment in the global market. An increased government effort to spread awareness regarding the treatment for lewy body dementia and the rising prevalence of brain-related disorders is foreseen to strengthen the market growth.